eXoZymes, Inc. Secures $2 million NIH Grant to Accelerate Cannabinoid Research

The biotechnology firm eXoZymes, Inc. (NASDAQ: EXOZ) announced on June 24, 2026 that it has been awarded a Phase IIB Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH), amounting to $2,028,518. The funding, granted by the National Institute of General Medical Sciences (NIGMS), will support the company’s program to manufacture rare cannabinoids and engineer cannabinoid analogs—modified compounds designed for pharmaceutical evaluation.

Grant Context and Timing

  • Start Date: The funded work is slated to commence on July 1, 2026.
  • Program Placement: This grant represents the second major biosolution in eXoZymes’ pipeline, following the NCT (nanocatalytic transformation) platform that is moving toward partnership and commercialization.
  • Cumulative Non‑Dilutive Funding: With this award, total non‑dilutive capital received by the company approaches $20 million, underscoring the scalability of its AI‑enhanced enzyme platform.

Strategic Significance

eXoZymes focuses on the development of enzyme modules and cell‑free exozyme biosolutions for synthetic biology manufacturing. The NIH grant validates the company’s capability to produce rare cannabinoids and novel cannabinoid‑like molecules—a segment of growing commercial interest. Market forecasts suggest the U.S. minor‑cannabinoid sector could expand from approximately $11.5 billion in 2023 to $33.3 billion by 2030, reflecting a compound annual growth rate of about 15 %. By positioning itself at the forefront of this expanding field, eXoZymes aims to convert scientific breakthroughs into future pharmaceutical assets.

Company Profile

  • Founded: 2014 (formerly Invizyne Technologies, Inc.)
  • Headquarters: Monrovia, California
  • Sector: Health Care
  • Market Cap (2026‑06‑22): $70.5 million
  • Close Price (2026‑06‑22): $7.70
  • 52‑Week Range (2025‑11‑09 to 2026‑06‑16): $18.40 – $6.33
  • Price‑to‑Earnings Ratio: –6.8 (reflecting development‑stage status)

Upcoming Investor Engagement

eXoZymes is scheduled to present at the Investor Summit Group’s Virtual Investor Summit on June 24, 2026. The presentation, slated for 10:00 AM ET, will provide an opportunity for institutional and retail investors to engage directly with management, discuss the implications of the NIH grant, and explore the company’s roadmap for scaling its enzyme‑based manufacturing platform.

This development reinforces eXoZymes’ position as a pioneer of AI‑enhanced enzymes that enable scalable production of nutraceuticals and novel pharmaceuticals. The grant not only fuels immediate research but also serves as a milestone in the company’s broader strategy to translate cutting‑edge biotechnological tools into tangible commercial opportunities.